The attorneys at Hollis Wright are currently investigating claims involving the use of the anti-coagulant, Pradaxa (Dabigatran). Recent FDA warnings have indicated that the use of Pradaxa may be related to serious G.I. bleeds that can result in extended hospital stays or even death. If you or a loved one has taken Pradaxa and experienced either an extended hospitalization for bleeding or a fatal bleeding incidence, please contact the attorneys at Hollis Wright today.
Manufactured by Boehringer Ingelheim, Dabigatran (known commercially as Pradaxa) was approved in October 2010 as an anticoagulant for patients suffering from most notably atrial fibrillation and/or prevention of strokes. Since the introduction of Pradaxa there have been numerous severe adverse event reports concerning Pradaxa use in patients. The adverse events have included things such as Internal Bleeding or Gastrointestinal Bleeding, Brain Hemorrhaging, Kidney Bleeding and even Death.
Pradaxa, not unlike Coumadin (Warfarin), is used in patients to prevent clotting. Both drugs carry the risk of gastrointestinal bleeding; however the rates of occurrence appear greater in those using Pradaxa. However, unlike Coumadin, Pradaxa has no antidote to reverse its anti-clotting properties. Therefore in case of an emergency situation, it can be extremely difficult, if not impossible, for a physician to reverse the anti-clotting effects of Pradaxa in time to save a person's life. Unfortunately this lack of an antidote has lead to serious injury and even death even in those who only suffered minor injuries due to the inability to stop internal bleeding once it starts.
If you or a loved one has taken Pradaxa and experienced either an extended hospitalization for bleeding or a fatal bleeding incidence, please contact the attorneys at Hollis Wright today.